<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        3105222112
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2001
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        PHYSIOTENS O.4 MG F.C.TAB
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        MOXONIDINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        0.4
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        65.15
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="ROTTENDORF PHARMA GMBH" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            ROTTENDORF PHARMA GMBH
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Abbott Laboratories GmbH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C02AC05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Physiotens 0.4 mg contains an active substance called moxonidine. This medicine belongs to a group of medicines called &ldquo;anti-hypertensives&rdquo;.</p><p>&nbsp;</p><p>Physiotens 0.4 mg is used to treat high blood pressure (hypertension). It works by relaxing and widening your blood vessels, an effect that will help to lower your blood pressure</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp; &nbsp;<strong> Do not take Physiotens 0.4 mg:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic (hypersensitive) to moxonidine or any of the other ingredients in this medicinal product mentioned in section 6.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if your heart rate is slow due to a heart problem called &ldquo;sick sinus syndrome&rdquo; or &ldquo;second or third degree AV block&rdquo;;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have heart failure.</p><p>&nbsp;</p><p>Do not take Physiotens 0.4 mg if any of the above apply to you. If you are not sure, talk to your doctor or pharmacist before taking Physiotens 0.4 mg.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist before taking your medicine:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a heart problem called &ldquo;first degree AV block&rdquo;;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have severe coronary artery disease or unstable chest pain (angina);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have kidney problems. Your doctor may need to adjust your dose.</p><p>&nbsp;</p><p>If any of the above apply to you (or you are not sure), talk to your doctor or pharmacist before taking Physiotens 0.4 mg.</p><p>&nbsp;</p><p><strong>Other medicines and Physiotens 0.4 mg</strong></p><p>Tell your doctor or pharmacist if you are taking or have recently taken any other medicines. This includes medicines obtained without a prescription, including herbal medicines. This is necessary because Physiotens 0.4 mg can affect the way other medicines work. Also, other medicines can affect the way Physiotens 0.4 mg works.</p><p>&nbsp;</p><p>It is particularly important to tell your doctor or pharmacist if you are taking any of the following medicines:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other medicines to lower your blood pressure. Physiotens 0.4 mg may increase the effect of these medicines.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines for depression, such as imipramine or amitriptyline.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tranquillisers, sedatives or sleeping tablets such as benzodiazepines.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Beta-blockers (see &ldquo;If you stop taking Physiotens 0.4 mg&rdquo; in section 3).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Physiotens 0.4 mg is removed from your body by your kidneys through a process called &ldquo;tubular excretion&rdquo;. Other medicines removed from the kidneys in the same way could affect how Physiotens 0.4 mg works.</p><p>&nbsp;</p><p>If any of the above apply to you (or you are not sure), talk to your doctor or pharmacist before taking Physiotens 0.4 mg.</p><p>&nbsp;</p><p><strong>Physiotens 0.4 mg with food and drink</strong></p><p>The tablets can be taken with or without food.</p><p>&nbsp;</p><p><strong>Pregnancy, &nbsp;breast-feeding and Fertility</strong></p><p>Tell your doctor if you are pregnant or might become pregnant. Your doctor will normally advise you to stop taking Physiotens 0.4 mg. Your doctor will advise you to take another medicine instead of Physiotens 0.4 mg.</p><p>&nbsp;</p><p>Tell your doctor if you are breast-feeding or about to start breast-feeding. Physiotens 0.4 mg is not recommended for mothers who are breast-feeding. Your doctor may advise you to take another medicine if you want to breast-feed, or may ask you to stop breast-feeding.</p><p>&nbsp;</p><p>If you are pregnant or breastfeeding, or if you suspect you are pregnant or intend to become pregnant, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>You may feel sleepy or dizzy while taking Physiotens 0.4 mg. If this happens, talk to your doctor before driving or using any tools or machines.</p><p>&nbsp;</p><p>Physiotens 0.4 mg contains lactose. If you have been told by your doctor that you cannot tolerate certain types of sugar, talk to your doctor before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Ask your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p><strong>Taking this medicine</strong></p><p>Swallow the tablets whole with a full glass of water.</p><p>Try to take your tablets at about the same time each day. This will help you remember to take them.</p><p>&nbsp;</p><p><strong>How much to take</strong></p><p>The usual starting dose is 0.2 mg a day.</p><p>Your doctor may increase this dose to up to 0.6 mg a day. f your doctor has told you to take 0.6 mg a day, this should be divided into two doses (0.3 mg in the morning and 0.3 mg in the evening).</p><p>The maximum single dose is 0.4 mg.</p><p>&nbsp;</p><p>Your doctor may tell you to take a lower dose if you have kidney problems.</p><p>&nbsp;</p><p><strong>Use in children and adolescents</strong></p><p>Physiotens 0.4 mg should not be given to children and adolescents under 18 years of age.</p><p>&nbsp;</p><p><strong>If you take more Physiotens 0.4 mg than you should</strong></p><p>If you take more Physiotens 0.4 mg than you should, talk to a doctor or go to a hospital straight away. Take the medicine with you. The following may develop: headache, feeling sleepy (somnolence, sedation), fall in blood pressure (hypotension), slow heart rate (bradycardia), feeling dizzy (vertigo), dry mouth, nausea (vomiting), feeling tired (fatigue), weakness and stomach ache (abdominal pain).</p><p>&nbsp;</p><p><strong>If you forget to take Physiotens 0.4 mg</strong></p><p>If you forget to take a dose, take it as soon as you remember. However, if it is nearly time for the next dose, skip the missed dose.</p><p>Do not take a double dose to make up for a forgotten dose.</p><p>&nbsp;</p><p><strong>If you stop taking Physiotens 0.4 mg</strong></p><p>Keep taking your tablets until your doctor decides that you should stop.</p><p>If you need to stop, your doctor will slowly lower your dose over a period of a few weeks. If you are taking more than one medicine for high blood pressure (such as beta-blockers), your doctor will tell you which medicine to stop first so that your body can slowly adjust to the change.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine also can cause side effects, although not everybody gets them. This medicine may cause the following side effects:</p><p>&nbsp;</p><p><strong>Stop taking Physiotens 0.4 mg and see a doctor straight away if you notice any of the following serious side effects &ndash; you may need urgent medical treatment:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the face, lips or mouth (angioedema). This is uncommon, affecting less than 1 in 100 people.</p><p>&nbsp;</p><p><strong>Other side effects include:</strong></p><p><strong>&nbsp;</strong></p><p><u>Very common (may affect more than 1 in 10 people)</u></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dry mouth</p><p>&nbsp;</p><p><u>Common (may affect up to 1 in 10 people)</u></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Back pain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weakness (asthenia)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Giddiness, dizziness (vertigo)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash or itching (pruritus)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sleep disorders (insomnia), sleepiness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea, diarrhoea, vomiting, indigestion</p><p>&nbsp;</p><p><u>Uncommon (may affect up to 1 in 100 people)</u></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Neck pain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nervousness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fainting (syncope)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling (oedema)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ringing or noises in the ears (tinnitus)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Unusually slow heartbeat (bradycardia)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low blood pressure, including low blood pressure when standing up</p><p>&nbsp;</p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p><p><strong>To report any side effect(s):</strong></p><p>- National Pharmacovigilance Center (NPC)</p><p>o&nbsp;&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>o&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>o&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>o&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa</p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1025" type="#_x0000_t75" style='width:490.35pt;height:108.4pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_3" o:spid="_x0000_s1026"
 type="#_x0000_t202" style='width:490.35pt;height:108.4pt;visibility:visible;
 mso-wrap-style:square;mso-left-percent:-10001;mso-top-percent:-10001;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:char;
 mso-position-vertical:absolute;mso-position-vertical-relative:line;
 mso-left-percent:-10001;mso-top-percent:-10001;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="#e3e3e3" strokeweight=".5pt">
 <v:textbox inset="0,0,0,0">
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal style='margin-top:.6pt'><span style='font-size:6.5pt;
    mso-ascii-font-family:Calibri;mso-fareast-font-family:Calibri;mso-hansi-font-family:
    Calibri;mso-bidi-font-family:Calibri'><o:p>&nbsp;</o:p></span></p>
    <p class=MsoNormal align=center style='margin-left:5.25pt;text-align:center'><b
    style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-family:Calibri;
    mso-bidi-theme-font:minor-latin'>To report any side effect(s):<o:p></o:p></span></b></p>
    <p class=MsoNormal align=center style='margin-left:5.25pt;text-align:center'><b
    style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-family:Calibri;
    mso-bidi-theme-font:minor-latin'>-National Pharmacovigilance Center (NPC)<o:p></o:p></span></b></p>
    <p class=MsoNormal align=center style='margin-left:5.25pt;text-align:center'><b
    style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-family:Calibri;
    mso-bidi-theme-font:minor-latin'>o Fax: +966-11-205-7662<o:p></o:p></span></b></p>
    <p class=MsoNormal align=center style='margin-left:5.25pt;text-align:center'><b
    style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-family:Calibri;
    mso-bidi-theme-font:minor-latin'>o SFDA Call Center: 19999<o:p></o:p></span></b></p>
    <p class=MsoNormal align=center style='margin-left:24.15pt;text-align:center;
    text-indent:-9.7pt;mso-list:l0 level1 lfo2'><![if !supportLists]><span
    style='font-size:10.0pt;font-family:"Courier New";mso-fareast-font-family:
    "Courier New";mso-bidi-font-weight:bold'><span style='mso-list:Ignore'>o<span
    style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span
    dir=LTR></span><b style='mso-bidi-font-weight:normal'><span
    style='mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>E-mail:
    <a name="_Hlk50038129"></a><a href="mailto:npc.drug@sfda.gov.sa"><span
    style='mso-bookmark:_Hlk50038129'>npc.drug@sfda.gov.sa</span><span
    style='mso-bookmark:_Hlk50038129'></span></a><span style='mso-bookmark:
    _Hlk50038129'></span><o:p></o:p></span></b></p>
    <p class=MsoNormal align=center style='margin-left:24.15pt;text-align:center;
    text-indent:-9.7pt;mso-list:l0 level1 lfo2'><![if !supportLists]><span
    style='font-size:10.0pt;font-family:"Courier New";mso-fareast-font-family:
    "Courier New";mso-bidi-font-weight:bold'><span style='mso-list:Ignore'>o<span
    style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span
    dir=LTR></span><b style='mso-bidi-font-weight:normal'><span
    style='mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'>Website:
    <a name="_Hlk50031886"></a><a href="https://ade.sfda.gov.sa"><span
    style='mso-bookmark:_Hlk50031886'>https://ade.sfda.gov.sa</span><span
    style='mso-bookmark:_Hlk50031886'></span></a><span style='mso-bookmark:
    _Hlk50031886'></span><o:p></o:p></span></b></p>
    <p class=MsoNormal align=center style='margin-left:5.25pt;text-align:center'><span
    style='mso-fareast-font-family:Arial;mso-bidi-font-family:Calibri;
    mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:shape><![endif]--></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children. Do not store above 30&deg;C.</p><p>Store in the original package.</p><p>Shelf life: 3 years</p><p>Do not use this medicine after the expiry date which is stated on the carton and blister strips. The expiry date refers to the last day of that month.</p><p>Do not dispose any medicines in wastewater or household waste. Ask your pharmacist how to dispose of the medicine if you stop using it. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is moxonidine. Each tablet contains 0.4 mg of moxonidine.</p><p>&nbsp;</p><p>The other ingredients are</p><p>Tablet core: Lactose monohydrate, povidone K25, crospovidone, magnesium stearate,</p><p>Tablet coating: Hypromellose, ethylcellulose, macrogol 6000, talc, red ferric oxide (E172), titanium dioxide (E 171).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                The film-coated tablets are round, convex, dull red, and marked “0.4” on one side.
 Physiotens 0.4 mg is available in packs of 28 or 98 film-coated tablets.
Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p>Abbott Laboratories GmbH, Hannover, Germany</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>Rottendorf Pharma GmbH,</p><p>Germany</p><p>&nbsp;</p><p><strong>Released by: </strong></p><p>Mylan Laboratories SAS</p><p>01400 Chatillon&shy;-Sur-&shy;Chalaronne&ndash; France</p><p>&nbsp;</p><p><strong>Packaged by:</strong></p><p>AJA Pharmaceutical Industries Company Ltd. (AJA Pharma)</p><p>Hail 55414 , Hail Industry City MODON</p><p>Kingdom of Saudi Arabia</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                04/2019 
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي فيزيوتنس &nbsp;0.4ملغم على مادة فعالة تسمى موكسونيدين. والذي ينتمي إلى مجموعة من الأدوية تسمى &quot;مضادات لضغط الدم المرتفع&quot;.&nbsp;</p><p>&nbsp;</p><p dir="RTL">فيزيوتنس 0.4 ملغم يستخدم لعلاج ارتفاع ضغط الدم. وهو يعمل عن طريق استرخاء وتوسيع الأوعية الدموية، والذي من شأنه أن يساعد على خفض ضغط الدم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لا تقم باستعمال فيزيوتنس </strong><strong>0.4</strong><strong> ملغم: </strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من فرط الحساسية (حساسية لموكسونيدين أو أي من السواغات الأخرى لدواء فيزيوتنس &nbsp;0.4ملغم) المدرجة في القسم 6.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان معدل ضربات القلب بطيئا بسبب مشكلة في القلب تسمى &quot; العقدة الجيبية المريضة &quot; أو&quot; الدرجة الثانية أو الثالثة من احصار انسداد القلب الأذيني البطيني.&quot;&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك قصور في القلب.</p><p dir="RTL">يجب عدم تناول هذا الدواء إذا كان أي مما سبق ينطبق عليك. إذا لم تكن متأكدا، تحدث مع طبيبك أو الصيدلي قبل تناول فيزيوتنس &nbsp;0.4ملغم.</p><p dir="RTL"><strong>التحذيرات والاحتياطات: </strong></p><p dir="RTL">تحدث إلى طبيبك أو إلى الصيدلي قبل تناول فيزيوتنس &nbsp;0.4ملغم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مشكلة في القلب تسمى احصار انسداد القلب الأذيني البطيني من الدرجة الأولى.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مرض شديد بالشريان التاجي أو ألم غير مستقر في الصدر (الذبحة الصدرية).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مشاكل في الكلى. قد يحتاج طبيبك إلى ضبط جرعتك.</p><p dir="RTL">إذا كان أي من ما سبق ينطبق عليك أو إذا لم تكن متأكدا، تحدث مع طبيبك أو الصيدلي قبل تناول فيزيوتنس &nbsp;0.4ملغم.&nbsp;</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>تناول أدوية أخرى مع فيزيوتنس </strong><strong>0.4</strong><strong> ملغم:&nbsp; </strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي أو الممرضة إذا كنت تناولت، أو قد تتناول مؤخرا أي أدوية أخرى، بما في ذلك الأدوية والأعشاب الطبية التي تم تناولها دون وصفة طبية، هذا ضروري لأن فيزيوتنس &nbsp;0.4ملغم يمكن أن تؤثر على طريقة عمل الأدوية الأخرى . أيضا، الأدوية الأخرى يمكن أن تؤثر على طريقة عمل فيزيوتنس &nbsp;0.4ملغم.&nbsp;</p><p dir="RTL">من المهم وبشكل خاص إخبار الطبيب أو الصيدلي إذا كنت تتناول أي من الأدوية التالية:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية أخرى لخفض ضغط الدم. تناول فيزيوتنس &nbsp;0.4ملغم قد يزيد من تأثير هذه الأدوية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية للاكتئاب، مثل إيميبرامين أو أميتريبتيلين.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المهدئات أو الأقراص المنومة مثل البنزوديازيبينات.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حاصرات بيتا انظر&quot; التوقف عن تناول فيزيوتنس 0.4 ملغم&quot; في القسم 3.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فيزيوتنس 0.4 ملغم يتم إزالتها (الإخراج) من جسمك عن طريق الكلى عن طريق عملية تسمى &quot;إفراز أنبوبي&quot;. الأدوية الأخرى التي يتم إزالتها من الكلى بنفس الطريقة يمكن أن تؤثر على كيفية عمل فيزيوتنس0.4 &nbsp;ملغم.</p><p dir="RTL">إذا كانت أي من الحالات السابقة تنطبق عليك أو إذا لم تكن متأكدا، تحدث مع طبيبك أو الصيدلي قبل تناول فيزيوتنس 0.4 ملغم.</p><p>&nbsp;</p><p dir="RTL"><strong>تناول فيزيوتنس </strong><strong>0.4</strong><strong> ملغم مع الطعام والشراب:&nbsp; </strong></p><p dir="RTL">يمكن تناول فيزيوتنس 0.4 ملغم مع أو بدون طعام.</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية والخصوبة: </strong></p><p dir="RTL">أخبر طبيبك إذا كنت حاملا أو قد تصبحين حاملا. سوف ينصحك الطبيب عادة بالتوقف عن تناول فيزيوتنس 0.4 ملغم. وستتوف ينصحك طبيبك بتناول دواء آخر بدلا من فيزيوتنس 0.4 ملغم.</p><p dir="RTL">أخبر طبيبك إذا كنت في مرحلة الرضاعة الطبيعية أو على وشك البدء في الرضاعة الطبيعية. لا ينصح بتناول فيزيوتنس 0.4 ملغم للأمهات اللاتي في مرحلة الرضاعة الطبيعية. قد ينصحك الطبيب بتناول دواء آخر إذا كنت ترغبين في الرضاعة الطبيعية، أو قد يطلب منك التوقف عن الرضاعة الطبيعية.</p><p dir="RTL">إذا كنت حاملا أو مرضعة، أو إذا كنت في شك من أنك حامل أو تنوي الحمل، اطلب من الطبيب أو الصيدلي الحصول على المشورة قبل تناول هذا الدواء.</p><p>&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات:&nbsp; </strong></p><p dir="RTL">قد تشعر بالنعاس أو بالدوار أثناء تناول فيزيوتنس 0.4 ملغم. إذا حدث ذلك، تحدث مع طبيبك قبل القيادة أو استخدام أي أدوات أو آلات.</p><p dir="RTL">فيزيوتنس 0.4 ملغم يحتوي على اللاكتوز. إذا أخبرك طبيبك إنك لا تستطيع تحمل أنواع معينة من السكر، تحدث مع طبيبك قبل تناول هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول دائمًا هذا الدواء كما وصف الطبيب لك، استشر طبيبك أو الصيدلي إن لم تكن متأكداً.</p><p dir="RTL"><strong>طريقة تناول هذا الدواء </strong></p><p dir="RTL">يتم ابتلاع الأقراص كاملة مع كوب كامل من الماء.</p><p dir="RTL">حاول أن تأخذ أقراصك في نفس الوقت تقريبا من كل يوم. هذا سوف يساعدك على تذكر أن تتناول الجرعة كل يوم.</p><p dir="RTL"><strong>الكمية التي يجب تناولها </strong></p><p dir="RTL">جرعة البداية المعتادة هي 0.2 ملغم يوميا.</p><p dir="RTL">قد يزيد طبيبك هذه الجرعة لتصل إلى 0.6 مجم يوميا. إذا أخبرك طبيبك أن تناول 0.6 ملغ يوميا، يجب تقسيمها إلى جرعتين 0.3 ملغم في الصباح و 0.3 ملغم في المساء.</p><p dir="RTL">&nbsp;الحد الأقصى للجرعة الواحدة هو 0.4 ملغم.</p><p dir="RTL">قد يخبرك طبيبك أن تتناول جرعة أقل إذا كان لديك مشاكل في الكلى.</p><p dir="RTL"><strong>الاستخدام للأطفال والمراهقين </strong></p><p dir="RTL">لا ينبغي أن تعطى فيزيوتنس 0.4 ملغم للأطفال والمراهقين تحت سن 18 سنة من العمر.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا تناولت جرعة زائدة من فيزيوتنس 0.4 ملغم:</strong></p><p dir="RTL">إذا تناولت فيزيوتنس 0.4 ملغم أكثر مما ينبغي، تحدث مع الطبيب أو اذهب إلى المستشفى على الفور. ويجب أخذ الدواء معك. قد تعاني مما يلي: الصداع، الشعور بالنعاس، التخدير، انخفاض ضغط الدم، بطء معدل ضربات القلب (بطء القلب)، الشعور بالدوار، جفاف الفم، الغثيان (القيء)، الشعور بالتعب ضعف وآلام في المعدة آلام في البطن. &nbsp;</p><p dir="RTL"><strong>إذا نسيت تناول فيزيوتنس 0.4 ملغم:</strong></p><p dir="RTL">إذا نسيت أن تتناول جرعة من الأقراص، تخطى تلك الجرعة الفائتة ثم تناول الجرعة التالية في موعدها.</p><p dir="RTL">لا تتناول جرعة مضاعفة لتعويض الجرعة المنسية. &nbsp;</p><p dir="RTL"><strong>التوقف عن تناول فيزيوتنس 0.4 ملغم:</strong></p><p dir="RTL">استمر في تناول أقراصك حتى يقرر طبيبك أن تتوقف.</p><p dir="RTL">إذا كنت بحاجة إلى التوقف عن تناول الدواء، سوف يقوم طبيبك بخفض جرعتك ببطء وعلى مدى فترة من بضعة أسابيع. إذا كنت تتناول أكثر من دواء لضغط الدم المرتفع (مثل حاصرات بيتا)، فإن طبيبك سيخبرك بالدواء الذي سيتوقف أولا حتى يتمكن الجسم من التكيف ببطء مع التغيير.</p><p dir="RTL">إذا كان لديك أية أسئلة أخرى حول هذا المنتج واستخدامه اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يتسبب هذا الدواء في آثار جانبية، على الرغم من أنها لا تؤثر في الجميع. الآثار الجانبية التالية قد تحدث مع تناول هذا الدواء:</p><p dir="RTL"><strong>يجب التوقف عن تناول فيزيوتنس 0.4 ملغم واستشر الطبيب أو اذهب إلى المستشفى على الفور إذا عانيت من الأعراض التالية، فقد تحتاج إلى علاج طبي عاجل: </strong></p><p dir="RTL">- تورم في الوجه والشفتين أو الفم (وذمة وعائية). هذا أمر غير شائع، حيث يؤثر على أقل من شخص من أصل 100 شخص.&nbsp;</p><p dir="RTL"><strong>أعراض جانبية أخرى وتشمل: </strong></p><p dir="RTL"><strong>شائعة جدا</strong> (قد تصيب أكثر من شخص من أصل 10 أشخاص)<strong> </strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف بالفم</p><p dir="RTL"><strong>شائعة</strong> (قد تصيب ما يصل إلى شخص من أصل 10 أشخاص)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الظهر</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع الراس</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الضعف (الوهن)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوخة، (الدوار)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي أو حكة&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات النوم (الأرق)، والنعاس</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان والإسهال والقيء وعسر الهضم</p><p dir="RTL"><strong>غير شائعة</strong> (قد تصيب ما يصل إلى شخص من أصل 100 شخص)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم الرقبة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العصبية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إغماء&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم (وذمة)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رنين أو ضوضاء في الأذنين (طنين)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بطء غير عادي وبشكل غير طبيعي في نبض القلب (بطء القلب)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم، بما في ذلك انخفاض ضغط الدم عند الوقوف</p><p dir="RTL">إذا زادت حدة أي من هذه الأعراض الجانبية، أو لاحظت ظهور أعراض جانبية غير ما تم ذكره في هذه النشرة، يرجى إبلاغ الطبيب المعالج أو الصيدلي. وهذا يشمل أي آثار جانبية محتملة غير مدرجة في هذه النشرة. بالإبلاغ عن الآثار الجانبية يمكنك المساعدة في توفير مزيد من المعلومات حول أمان هذا الدواء.&nbsp;</p><p><strong>To report any side effect(s):</strong></p><p>- National Pharmacovigilance Center (NPC)</p><p>o&nbsp;&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>o&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>o&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>o&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ بعيدا عن متناول أيدي الأطفال أو على مرأى منهم.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ في درجة حرارة أقل من 30 درجة مئوية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خزن الدواء في علبته الأصلية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فترة الصلاحية: 3 سنوات.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم فيزيوتنس 0.4 ملغم بعد انتهاء تاريخ الصلاحية المذكور على العبوة الخارجية. تاريخ انتهاء الصلاحية يشير إلى اليوم الأخير من ذلك الشهر.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا ينبغي أن يتم التخلص من الأدوية في مياه الصرف الصحي أو عن طريق النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد مطلوبة. هذه التدابير تساعد في الحفاظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي موكسونيدين. حيث يحتوي كل قرص على 0.4 ملغم من موكسونيدين.</p><p dir="RTL">السواغات الأخرى هي:</p><p dir="RTL">لب القرص: لاكتوز وحيد التمية، بوفيدون K25 ، كروسبوفيدون، استيارات المغنيسيوم،</p><p dir="RTL">غلاف القرص: هيبروميلوز، سليلوز الإتيل، ماكروغول 6000، طلق، أكسيد حديد أحمر (E172) ، ثاني أكسيد التيتانيوم (E171).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">فيزيوتنس 0.4 ملغم عبارة عن أقراص مغلفة بطبقة رقيقة مستديرة، و محدبة ذات اللون الأحمر الكامد، محفور عليها علامة&quot;0.4&quot; على جانب واحد.</p><p dir="RTL">يتم توفير فيزيوتنس 0.4 ملغم في عبوة تحتوي على 28 أو 98&nbsp; أقراص مغلفة بطبقة رقيقة.</p><p dir="RTL">قد لا تتوافر كافة العبوات في السوق &nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>صاحب حق التسويق: </strong></p><p dir="RTL">أبوت لابوراتوريز جي إم بي إتش، هانوفر، ألمانيا</p><p dir="RTL">&nbsp;<strong>المصنع:&nbsp; </strong></p><p dir="RTL">روتيندورف للأدوية &ndash; ألمانيا</p><p dir="RTL"><strong>مطلقة من قبل:</strong></p><p dir="RTL">مايلان لابوراتوريز إس أ إس&nbsp;</p><p dir="RTL">٠١٤٠٠ شاتيلون سور شارالاون ، فرنسا</p><p dir="RTL"><strong>تم التغليف في: </strong></p><p dir="RTL">شركة اجا للصناعات الدوائية المحدودة (اجا فارما(</p><p dir="RTL">حائل ٥٥٤١٤، المدينة الصناعية &ndash; حائل</p><p dir="RTL">المملكة العربية السعودية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            04/2019
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Physiotens® 0.4 mg, film-coated tablets

Active substance: Moxonidine

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Physiotens 0.4 mg:
Each film-coated tablet contains 0.4 mg moxonidine.

Other ingredients with known effects: Lactose monohydrate

For full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablets
Physiotens 0.4 mg:
Round, convex, dull red, film-coated tablets with “0.4” embossed on one side
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For the treatment of primary forms of arterial hypertension or arterial hypertension with no recognisable cause (essential hypertension).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Moxonidine should be dosed on an individual basis. The therapeutic daily dose is usually between 0.2 mg moxonidine and 0.4 mg moxonidine.</p><p><strong>&nbsp;</strong></p><p>Treatment should be started at the lowest dose of moxonidine, i.e. 0.2 mg moxonidine per day, corresponding to1 film-coated tablet of Physiotens 0.2 mg in the morning.</p><p>&nbsp;</p><p>If the effect is inadequate, the dose should be increased after 3 weeks at the earliest to 0.4 mg moxonidine per day, corresponding to 2 film-coated tablets of Physiotens 0.2 mg in the morning or 1 film-coated tablet of Physiotens 0.2 mg twice daily (1 film-coated tablet in the morning, 1 film-coated tablet in the evening).</p><p>&nbsp;</p><p>If a higher daily dose is indicated, Physiotens 0.3 mg and Physiotens 0.4 mg are available to simplify usage.</p><p>&nbsp;</p><p>A single dose of 0.4 mg moxonidine and a daily dose of 0.6 mg moxonidine should not be exceeded.</p><p>&nbsp;</p><p><em>Impaired kidney function:</em></p><p>In patients with moderately impaired kidney function (GFR higher than 30 ml/min but less than 60 ml/min), a single dose of 0.2 mg moxonidine and a daily dose of 0.4 mg moxonidine should not be exceeded.</p><p>&nbsp;</p><p>In haemodialysis patients, the initial dose is 0.2 mg daily. If necessary and it is well tolerated, in patients with moderately impaired kidney function the dose can be increased to 0.4 mg daily and in patients with severe kidney impairment to 0.3 mg daily (see section 4.4).</p><p>&nbsp;</p><p><em>Impaired liver function:</em></p><p>So far there are no studies on patients with impaired liver function. As moxonidine is not liable to extensive liver metabolism, no substantial effect on pharmacokinetics is expected. Therefore the recommended dose for patients with mild to moderate liver damage corresponds to the normal dose recommendation for adults.</p><p>&nbsp;</p><p><em>Children and Adolescents:</em></p><p>Because of the lack of data on safety and efficacy, the use of moxonidine in children and adolescents under 18 years of age is not recommended.</p><p>&nbsp;</p><p>Method of Administration</p><p>&nbsp;</p><p>The film-coated tablets should preferably be taken with sufficient fluid. They may be taken with or without food.</p><p>&nbsp;</p><p>No time limit on duration of use is envisaged.</p><p>&nbsp;</p><p>Although in a limited number of studies, following sudden discontinuation of moxonidine, no counter-regulation of blood pressure (rebound effect) was noted, it is not recommended - as is usual with all antihypertensives - that the treatment with moxonidine is ended abruptly in case this is necessary. Moxonidine should be discontinued by reducing it over a period of 2 weeks.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Moxonidine should not be used in the case of:
•	sick sinus syndrome
•	2nd and 3rd degree atrioventricularblock
•	resting bradycardia below 50 beats a minute
•	cardiac insufficiency
•	Hypersensitivity to the active substance or to any of the excipients listed in section 6.1

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>After market launch, cases of AV block of varying degree have been reported in patients treated with moxonidine. Because of these case reports, a contributory role of moxonidine in delayed atrioventricular conduction cannot be ruled out. Caution is therefore advisable in the treatment of patients in whom a tendency to develop an AV block is possible.</p><p>&nbsp;</p><p>If moxonidine is used in patients with 1<sup>st</sup> degree atrioventricularblock, care must be taken in particular to avoid bradycardia. Moxonidine should not be used in cases of AV block of a higher degree (see section 4.3).</p><p>&nbsp;</p><p>When using moxonidine in patients with severe coronary artery disease or unstable angina pectoris, special care is required, as there is only limited experience with this patient population.</p><p>&nbsp;</p><p>When using moxonidine in patients with kidney damage, caution is advisable since moxonidine is eliminated primarily through the kidneys. In these patients, especially at the start of therapy, care should be exercised when increasing the dose. The dose should be started at 0.2 mg daily and in patients with moderately impaired kidney function (GFR &gt; 30 ml/min but &lt; 60 ml/min) can be increased to a maximum of 0.4 mg daily and in patients with severely impaired kidney function (GFR &lt; 30 ml/min) to 0.3 mg daily, if this is indicated clinically and is well tolerated.</p><p>&nbsp;</p><p>If moxonidine is used with a beta-blocker and both therapies have to be terminated, the beta-blocker should be stopped first and then the moxonidine a few days later.</p><p>&nbsp;</p><p>So far no rebound effect on blood pressure has been noted after stopping moxonidine therapy. However, abrupt termination of treatment with moxonidine is not advisable; it is better to reduce the dose gradually over a period of two weeks.</p><p>&nbsp;</p><p>Patients with the rare hereditary galactose intolerance, lactase deficiency or glucose-galactose malabsorption should not take Physiotens.</p><p>&nbsp;</p><p>Older people may be more sensitive to the effect of antihypertensives. Therefore the therapy should be started at the lowest dose and the dose should be carefully increased in order to avoid serious secondary reactions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Co-administration of other antihypertensives increases the hypotensive effect of moxonidine.</p><p>As tricyclic antidepressantscan reduce the effect of centrally acting antihypertensives, concomitant administration of tricyclic antidepressantswith moxonidine is not recommended.</p><p>Moxonidine can potentiate the sedative effect of tricyclic antidepressants (co-prescribing should be avoided), tranquillisers, alcohol, sedatives and hypnotics.</p><p>Moxonidine moderately increases loss of cognitive performance in test subjects who received lorazepam. Moxonidine can increase the sedative effect of benzodiazepines when administered at the same time.</p><p>Moxonidine is eliminated by tubular secretion. Interaction with other substanceseliminated by tubular secretion cannot be ruled out. However, studies with digoxin and hydrochlorothiazide did not reveal any evidence of interactions. Oral bioavailability of glibenclamide was reduced by 11%.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy:</p><p>There are no adequate data on the use of moxonidine in pregnant women. Studies on animals have revealed embryotoxic effects (see section 5.3). The potential risk for humans is unknown. Moxonidine should be used in pregnancy only if clearly necessary.</p><p>Breast-feeding:</p><p>Moxonidine is excreted in breast milk and should therefore not be used when breastfeeding. If therapy with moxonidine is considered essential, weaning is necessary.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been carried out.</p><p>&nbsp;</p><p>The treatment of arterial hypertension with this medicinal product requires regular medical supervision. Because of various reactions that occur in individual cases (e.g. dizziness, drowsiness), responsiveness can be changed to such an extent that the ability to drive, use machines or work without secure support is affected. This applies even more so at the start of treatment, if the dose is increased or the medication changed, and during interaction with alcohol.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The undesirable effects most commonly reported when taking moxonidine include dry mouth, dizziness, asthenia and somnolence. These effects normally diminish after the first few weeks of treatment.</p><p>&nbsp;</p><p>Undesirable effects according to system organ class: Class <em>(The following undesirable effects were noted in placebo-controlled clinical trials with n=866 patients who received moxonidine and at the following frequencies):</em></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:597px"><tbody><tr><td style="vertical-align:top"><p>System organ class according to MedRA</p></td><td style="vertical-align:top"><p>Very common</p><p>(</p><p>can occur in</p><p>more than 1 in 10</p><p>patients treated)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p><p>(can occur in</p><p>&nbsp;up to 1 in 10 patients treated)</p></td><td style="vertical-align:top"><p>Uncommon</p><p>(can occur in</p><p>up to 1 in 100 patients treated)</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Bradycardia</p></td></tr><tr><td style="vertical-align:top"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Tinnitus</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Headache*, dizziness/vertigo, somnolence</p></td><td style="vertical-align:top"><p>Syncope*</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypotension* (including orthostatic hypotension)</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Dry mouth</p></td><td style="vertical-align:top"><p>Diarrhoea, nausea/vomiting/dyspepsia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Erythema, pruritus</p></td><td style="vertical-align:top"><p>Angioedema</p></td></tr><tr><td style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Asthenia</p></td><td style="vertical-align:top"><p>Oedema</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Back pain</p></td><td style="vertical-align:top"><p>Neck pain</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Insomnia</p></td><td style="vertical-align:top"><p>Nervousness</p></td></tr></tbody></table><p>* The frequency was not increased compared with placebo.</p><p>&nbsp;</p><p>Reporting of suspected undesirable effects.</p><p>The reporting of suspected undesirable effects after authorisation is of great importance. It enables continuous monitoring of the medicinal product&rsquo;s risk-benefit ratio. Healthcare professionals are asked to report every suspected case of an undesirable effect&nbsp;</p><p><strong>To report any side effect(s):</strong></p><p>- National Pharmacovigilance Center (NPC)</p><p>o&nbsp;&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>o&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>o&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>o&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>However, in some cases acute doses of up to 19.6 mg were taken without a fatal development. The reported signs and symptoms of overdose are: headache, sedation, somnolence, hypotension, dizziness, asthenia, bradycardia, dry mouth, vomiting, fatigue and upper abdominal pain. In the case of a heavy overdose, close monitoring is recommended, particularly for disorders of consciousness and respiratory depression.</p><p>&nbsp;</p><p>In the case of a 2-year old child who had accidentally ingested an unknown quantity of moxonidine (potentially 14 mg), sedation, coma, hypotension, miosis and dyspnoea occurred. Gastrolavage, a glucose infusion, controlled respiration and immobilisation led to complete remission of the symptoms within 11 hours.</p><p>&nbsp;</p><p>On the basis of animal trials at high doses, the following symptoms are also possible: orthostatic dysregulation, paradoxical hypertension, tachycardia and hyperglycaemia.</p><p>&nbsp;</p><p><em>Treatment of intoxication:</em></p><p>A specific antidote is not known. If there is a fall in blood pressure, circulatory support, for example with administration of fluid and dopamine, may be indicated. Bradycardia can be treated with atropine.</p><p>&nbsp;</p><p>&alpha;-receptor antagonists can reduce or annul the paradoxical hypertensive effect of moxonidine overdose.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Imidazoline receptor agonist, moxonidine</p><p>ATC code: C02AC05</p><p>&nbsp;</p><p>In various animal models, moxonidine proved to be a highly effective antihypertensive. The available data from experimental studies clearly show that the site of action for the antihypertensive effect of moxonidine is the central nervous system (CNS). It has been established that moxonidine in the brain stem binds selectively to I<sub>1</sub>-imidazoline receptors. These imidazoline receptors are concentrated in the rostral ventrolateral medulla, an area of decisive significance in central control of the peripheral sympathetic nervous system. The binding of moxonidine to the I<sub>1</sub>-imidazoline receptor has an inhibiting effect on the activity of the sympathetic nerves (demonstrated in sympathetic nerve endings of the heart, internal organs and kidneys). In humans, through a reduction in the sympathetic nerve activity, moxonidine leads to a reduction in systemic vascular resistance and consequently to a lowering of arterial blood pressure. The effects of moxonidine on mortality and cardiovascular morbidity during treatment of essential hypertension are currently unknown.</p><p>Moxonidine differs from other available centrally acting antihypertensives in a lesser affinity for central alpha-2 receptors compared with I<sub>1</sub>-imidazoline receptors; the undesirable effects of fatigue and dry mouth are attributed to the interaction with alpha-2 receptors. Because of the high selectivity for imidazoline receptors, undesirable effects such as sedation and dry mouth resulting from the interaction with alpha-2 receptors - the most commonly occurring undesirable effects of centrally acting antihypertensives - are clearly less pronounced.</p><p>Published data prove that in hypertensive patients with left ventricular hypertrophy (LVH) who have had an angiotensin-II-antagonist (AIIA) administered together with moxonidine to lower blood pressure, improved LVH reduction is achieved compared with the free combination of a thiazide and a calcium channel blocker.</p><p>In a two-month clinical study, moxonidine, in comparison with placebo, improved the insulin-sensitivity index of overweight and insulin-resistant patients with moderate hypertension by 21%.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Absorption:</em></p><p>Following oral administration, moxonidine is quickly and almost completely absorbed into the upper gastrointestinal tract (t<sub>max</sub> approx. 1 hour), it does not undergo any first-pass metabolism and is therefore 88% bioavailable. Ingestion of food has no effect on the pharmacokinetics of moxonidine.</p><p>&nbsp;</p><p><em>Distribution:</em></p><p>The maximum moxonidine plasma levels are reached 30 to 180 minutes after administration of the film-coated tablets.</p><p>Following in vitro measurements, human plasma protein binding to moxonidine is only about 7.2% (Vd<sub>ss</sub> = 1.8 +/- 0.4 l/kg).</p><p>&nbsp;</p><p><em>Biotransformation:</em></p><p>Moxonidine is metabolised up to 10 - 20%, in fact mainly to 4,5-dehydromoxonidine and through opening of the imidazoline ring to guanidine derivative. 4,5-dehydro-moxonidine shows only 1/10 and guanidine derivative less than 1/100 of the hypotensive efficacy of moxonidine.</p><p>&nbsp;</p><p><em>Elimination:</em></p><p>Moxonidine and its metabolites are eliminated almost exclusively by the kidneys. Over 90% of the applied activity dose is eliminated by the kidneys in the first 24 hours after administration; in comparison, only about 1% through faeces. Cumulative renal elimination of unchanged moxonidine in the process amounts to approximately 50-75%.</p><p>The mean plasma elimination half-life of moxonidine is 2.2 to 2.3 hours; the renal elimination half-life is 2.6 to 2.8 hours.</p><p>It has been shown that under moxonidine, in spite of the renal elimination, no accumulation occurs either with repeated application or with impaired kidney function.</p><p>&nbsp;</p><p><em>Pharmacokinetics in hypertensive patients:</em></p><p>In hypertensive patients, no relevant changes were noted in the pharmacokinetics compared with healthy test subjects.</p><p>&nbsp;</p><p><em>Pharmacokinetics in elderly patients:</em></p><p>The slight difference in the pharmacokinetic properties of moxonidine in healthy older patients and young adults has so far proven to be clinically irrelevant. As moxonidine does not have a tendency to accumulate, no dose adjustment is necessary, if kidney function is normal.</p><p>&nbsp;</p><p><em>Pharmacokinetics in children:</em></p><p>So far no pharmacokinetic studies have been carried out on children.</p><p>&nbsp;</p><p><em>Pharmacokinetics in patients with impaired kidney function:</em></p><p>There is a significant correlation between moxonidine elimination and creatinine clearance. In patients with impaired kidney function, the dose has to be adjusted to individual requirements.</p><p>In patients with moderately impaired kidney function (GFR 30-60 ml/min), the AUC is increased by 85%, clearance is reduced by 52% and steady-state plasma concentration and terminal half-life are increased approximately 2-fold or 1.5-fold compared with hypertensive patients with normal kidney function (GFR &gt; 90 ml/min). The maximum moxonidine plasma concentrations are increased by only 1.5 to 2-fold.</p><p>&nbsp;</p><p>In patients with severe kidney damage (GFR &lt; 30 ml/min), steady-state plasma concentrations and terminal half-life are approximately three times higher. In these patients, no unexpected drug accumulation was noted after multi-dosing. In kidney patients in the terminal stage (GFR &lt; 10 ml/min) who undergo haemodialysis, AUC and terminal half-life are increased 6-fold or 4-fold compared with hypertensive patients with normal kidney function.</p><p>&nbsp;</p><p>Moxonidine is eliminated to a lesser extent through haemodialysis</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Based on the conventional studies on safety pharmacology, chronic toxicity, reproductive toxicity, genotoxicity and carcinogenic potential, the preclinical data do not indicate any particular risk for humans.</p><p>&nbsp;</p><p>Experimental studies on animals have shown embryotoxic effects at maternally toxic doses.</p><p>&nbsp;</p><p>Reproductive studies did not reveal any impaired fertility or teratogenic effects.</p><p>&nbsp;</p><p>Embryotoxic effects were observed in rats in the dose range above 3 mg/kg of body weight daily and in rabbits above 0.7 mg/kg of body weight daily.</p><p>&nbsp;</p><p>In a peri- and post-natal study on rats, development and viability of the young were impaired at doses above 1 mg/kg of body weight daily.</p><p>&nbsp;</p><p>Carcinogenicity studies on rats at doses up to 3.6 mg/kg of body weight daily and on mice up to 7.5 mg/kg of body weight daily revealed no evidence of a carcinogenic risk through moxonidine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tablet core:</p><p>Crospovidone Type A (Ph. Eur.)</p><p>Lactose monohydrate</p><p>Magnesium stearate (Ph. Eur.) [vegetable]</p><p>Povidone (K25)</p><p>&nbsp;</p><p>Film-coating:</p><p>Red iron oxide (E172)</p><p>Ethylcellulose</p><p>Hypromellose</p><p>Macrogol 6000</p><p>Talc</p><p>Titanium dioxide (E171)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PVC aluminium blister pack or PVC/PVDC aluminium blister pack</p><p>&nbsp;</p><p>Original packagings with:</p><p>- 28 film-coated tablets</p><p>- 98 film-coated tablets</p><p>Not all pack sizes may be marketed</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Abbott Laboratories GmbH,
Hannover, Germany

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                11/2019
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>